$1.53
0.66% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US29479A1088
Symbol
ERAS
Sector
Industry

Erasca Inc Stock price

$1.53
+0.14 10.07% 1M
-1.10 41.83% 6M
-0.98 39.04% YTD
-0.69 31.08% 1Y
-15.90 91.22% 5Y
-15.90 91.22% 10Y
-15.90 91.22% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.01 0.66%
ISIN
US29479A1088
Symbol
ERAS
Sector
Industry

Key metrics

Market capitalization $433.43m
Enterprise Value $128.84m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.08
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-178.57m
Free Cash Flow (TTM) Free Cash Flow $-107.82m
Cash position $304.59m
EPS (TTM) EPS $-0.55
P/E forward negative
Short interest 8.62%
Show more

Is Erasca Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Erasca Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Erasca Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Erasca Inc forecast:

Buy
100%

Financial data from Erasca Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 39 39
2% 2%
-
- Research and Development Expense 110 110
5% 5%
-
-175 -175
25% 25%
-
- Depreciation and Amortization 3.63 3.63
5% 5%
-
EBIT (Operating Income) EBIT -179 -179
25% 25%
-
Net Profit -158 -158
24% 24%
-

In millions USD.

Don't miss a Thing! We will send you all news about Erasca Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Erasca Inc Stock News

Neutral
GlobeNewsWire
11 days ago
Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializin...
Neutral
GlobeNewsWire
15 days ago
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and will also participate in one-on-one investor mee...
Neutral
GlobeNewsWire
about one month ago
Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE...
More Erasca Inc News

Company Profile

Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Jonathan Lim
Employees 126
Founded 2018
Website www.erasca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today